Group items matching

in title, tags, annotations or url

Britain's biotech firm Avacta Group on Monday (January 10) announced halting sales of its Covid-19 rapid antigen lateral flow test AffiDX to replace antibodies in the device and increase its ability to diagnose the Omicron variant. The company stated that AffiDX is capable of detecting Omicron when the virus is present in high numbers in samples, but the sensitivity of the test reduces at lower viral loads. The performance of all rapid antigen tests came under scanner in wake of a large number of mutations in the Omicron variant. AffiDX contains both a proprietary Affimer reagent and a commercially available antibody. The Affimer reagent detects the Omicron variant with the same sensitivity as the Delta variant, and performance of the antibody is paired with the Affimer reagent in the test. This has been affected by the additional Omicron mutations, the firm said. Alastair Smith, chief executive of Avacta Group, said: "Our determination to only provide high quality, high performance diagnostic tests has led us to the correct decision to pause all marketing of the AffiDX® lateral flow antigen test. We have, of course, been unable to market the product in the UK since October 2021, as the product continues to await approval under the new CTDA regulatory process.

The best interventional neurologist in Delhi India specializes in the prevention, diagnosis, treatment, and rehabilitation of disorders that affect the spinal cord and peripheral nerves. He is an expert in determining if surgery is the best course of treatment and offers the latest techniques in spinal surgery and microsurgery of herniated discs, spinal stenosis, and tumors.

UK regulator has approved a second oral antiviral for early treatment of Covid-19 in high-risk adults, after molnupiravir. The Medicines and Healthcare products Regulatory Agency (MHRA) gave its nod for a new treatment called Paxlovid (PF-07321332 and ritonavir), after finding it safe and effective at reducing the risk of hospitalisation and death in people diagnosed with mild Covid-19 infection. Developed by Pfizer, Paxlovid prevents the multiplying of virus, helping the body to overcome the infection. A clinical trial for the treatment in high risk individuals revealed that a five-days course of Paxlovid reduces the risk of hospitalisation and death by 89 per cent. It further revealed that Paxlovid is most effective when taken in the early stage of infection. Dr June Raine, MHRA chief executive, said: "We now have a further antiviral medicine for the treatment of Covid-19 that can be taken by mouth rather than administered intravenously. This means it can be administered outside a hospital setting, before Covid-19 has progressed to a severe stage."

Dr. Vipul Gupta possesses expertise in determining whether surgery is the optimal course of treatment. He employs the latest techniques in spinal surgery and microsurgery for conditions like herniated discs, spinal stenosis, and tumors. The best interventional neurologist in Delhi India is committed to integrating innovative technologies into the care and treatment of his patients.

another mouse study that found that increasing telomerase activity in shortened telomere mice improved tissue regeneration.

Zn show to help in glycemic control in both type I and II diabetics.  It appears to do this through inflammation reduction and thus improved insulin/Receptor signal transduction.   Also of note, antibodies against Zn transporter have been found in type I DM.

here is the full article in pdf form

If you understand the importance of people making the right first impression, you'll understand the need for them also having clean and white teeth.

to be read